Arbutus Biopharma Q3 2026 Results: Turns Profitable, Net Income $59.1M
Arbutus Biopharma reported a significant net income of $223.7 million for the nine months ended September 30, 2026, primarily driven by a $178.4 million settlement payment from Moderna and $67.3 million in dividend income. This represents a major turnaround from a net loss of $29.7 million in the prior year period, significantly strengthening the company's cash position to $264.2 million.
- Key figure
- Net income $59.1M